v3.26.1
Business Combination - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
2 Months Ended 3 Months Ended 12 Months Ended
Feb. 12, 2026
Mar. 31, 2026
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2025
Business Combination [Line Items]          
Total revenues     $ 392,911 $ 306,510  
Net Income (Loss)     (66,480) $ 22,464  
Avadel Pharmaceuticals Plc          
Business Combination [Line Items]          
Business combination, price per share $ 21        
Business combination, contingent consideration, additional cash payment per share $ 1.5        
Contingent payments $ 165,700        
Contingent consideration liability 107,700        
Purchase price 134,900        
Recognized share-based compensation expense 20,200        
Total revenues   $ 39,500      
Net Income (Loss)   16,200      
Deferred tax liability 183,129 183,100 183,100    
Deferred tax assets 1,244 1,200 1,200    
Transaction costs   $ 34,800 34,800    
Direct one-time transaction costs     $ 77,700    
Direct one-time acquisition transaction costs 44,500       $ 9,700
Acceleration of unvested share-based compensation awards $ 20,200